Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Phio Pharmaceuticals Corp. (PHIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1800-0.0600 (-4.84%)
At close: 04:00PM EST
1.1900 +0.01 (+0.85%)
After hours: 07:52PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.2400
Open1.2500
Bid1.1700 x 1400
Ask1.1900 x 2200
Day's Range1.1700 - 1.2500
52 Week Range1.1700 - 4.3600
Volume173,241
Avg. Volume389,441
Market Cap15.971M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PHIO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Phio Pharmaceuticals Corp.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features the future of oil demand; shopping for Nordstrom stock; med-tech valuations; and notes from Gilead Sciences, Imperial Brands, and Millicom.
    Rating
    Fair Value
    Economic Moat
    14 days agoMorningstar
View more
  • PR Newswire

    Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual Meeting

    Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new study data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting. The data from this study in an in vivo hepatocarcinoma model shows that PH-762 administered locally clears untreated distal tumors, indicating a systemic immune response.

  • PR Newswire

    Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

    Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended September 30, 2021 and provided a business update.

  • PR Newswire

    Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting

    Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that new data suggesting a systemic immune response can be generated with its lead clinical product candidate, PH-762, after local administration. These data will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, being held in Washington, D.

Advertisement
Advertisement